Assure Holdings Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04625J3032
USD
0.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Assure Holdings Corp. stock-summary
stock-summary
Assure Holdings Corp.
Pharmaceuticals & Biotechnology
Assure Holdings Corp, formerly Montreux Capital Corp, is a Canada-based company that works with neurosurgeons and orthopedic spine surgeons to provide a suite of services that support intraoperative neuromonitoring activities during invasive surgeries. The Company offers Intraoperative Neurophysiologic Monitoring (IONM) techniques to identify changes in brain, spinal cord, and/or peripheral nerve function in order to prevent complications that could result in irreversible nerve damage, during surgeries. The Company’s technologists are trained to monitor: Neurological Surgeries, such as aneurysms, brain tumors and lumbar fusion, among others; Otolaryngology Surgeries, such as acoustic neuroma, parotidectomy and tympanomastoidectomy, as well as Orthopedic Surgeries.
Company Coordinates stock-summary
Company Details
4600 S Ulster St Ste 1225 , DENVER CO : 80237
stock-summary
Tel: 1 720 28730391 720 2873093
stock-summary
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (0.79%)

Foreign Institutions

Held by 2 Foreign Institutions (0.36%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. John Farlinger
Executive Chairman of the Board, Chief Executive Officer
Mr. Preston Parsons
Founder, Director
Mr. Martin Burian
Independent Director
Dr. Christopher Rumana
Independent Director
Mr. Steven Summer
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2024)
Net Profit:
-4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.83

stock-summary
Return on Equity

105.35%

stock-summary
Price to Book

-0.01